Novabay Pharmac | 10-Q: FY2025 Q3 Revenue: USD 521 K

Revenue: As of FY2025 Q3, the actual value is USD 521 K.

EPS: As of FY2025 Q3, the actual value is USD -0.22.

EBIT: As of FY2025 Q3, the actual value is USD -1.179 M.

Segment Revenue

• Product Revenue, Net: $521,000 for the three months ended September 30, 2025, with no comparable revenue in the same period of 2024.

Operational Metrics

• Gross Profit: $42,000 for the three months ended September 30, 2025, with no comparable gross profit in the same period of 2024.
• Operating Loss: - $1,256,000 for the three months ended September 30, 2025, compared to - $1,703,000 for the same period in 2024, a decrease of 26%.
• Net Loss from Continuing Operations: - $1,333,000 for the three months ended September 30, 2025, compared to - $1,854,000 for the same period in 2024, a decrease of 28%.

Cash Flow

• Net Cash Used in Operating Activities, Continuing Operations: - $6,155,000 for the nine months ended September 30, 2025, compared to - $5,821,000 for the same period in 2024.
• Net Cash Used in Financing Activities, Continuing Operations: - $3,201,000 for the nine months ended September 30, 2025, compared to $999,000 provided by financing activities for the same period in 2024.

Unique Metrics

• Impairment of Long-Lived Assets: $87,000 for the three months ended September 30, 2025, with no comparable impairment in the same period of 2024.

Future Outlook and Strategy

• Core Business Focus: The company plans to continue manufacturing wound care products domestically in the United States and exporting finished goods to China.
• Non-Core Business: The company is evaluating opportunities within emerging financial infrastructure and network-based markets, which may include select blockchain-based assets.
• Priority: Management believes that the company’s existing cash and cash equivalents will be sufficient to meet its planned operating expenses at least through November 7, 2026.